Clinical Drug Investigation

, Volume 10, Supplement 1, pp 1–6 | Cite as

Quality-of-Life Issues and Economic Burden of Psoriasis and Atopic Dermatitis

Rationale for Treatment
  • A. Y. Finlay


Both psoriasis and atopic dermatitis are common skin disorders that have profound social and economic effects on the patients and their families. Surveys of the effects of these diseases have demonstrated their interference with social life, sport, caring for the home, personal and sexual relationships, and the ability to work. These effects are similar across many cultures. Methods of measuring the impact of psoriasis and atopic dermatitis on quality of life include disease-specific indices such as the Psoriasis Disability Index, specialty-specific indices such as the Dermatology Life Quality Index, general health measures such as the UK Sickness Impact Profile, and utility measures. Both diseases score more highly than other skin conditions, and result in handicap levels equivalent to those experienced by patients with nondermatological diseases such as hypertension and angina. The use of these measures in psoriasis and atopic dermatitis has shown an improvement in handicap levels resulting from inpatient admission and from treatment with cyclosporin. These diseases can have an immediate effect on earnings and a long term effect on career choices and employment opportunities. Cost analysis of management strategies highlights the financial advantages of daycare outpatient treatment centres and provides a financial ranking of the different topical and systemic approaches to the treatment of psoriasis. The costs of treatment must be considered in relation to the degree of benefit gained in terms of handicap reduction and restored earning capacity, and not simply in terms of the unit cost of therapy.


Psoriasis Adis International Limited Atopic Dermatitis Dermatol Drug Invest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Russell PS. Dermatology in the Oregon Plan with implications for health care plans in other states. Arch Dermatol 1994; 130: 709–12PubMedCrossRefGoogle Scholar
  2. 2.
    Ingram JT. The significance and management of psoriasis. BMJ 1954; II: 823–8CrossRefGoogle Scholar
  3. 3.
    Ginsburg IH, Link BG. Feelings of stigmatisation in patients with psoriasis. J Am Acad Dermatol 1989; 20: 53–63PubMedCrossRefGoogle Scholar
  4. 4.
    Ramsay B, O’Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988; 118: 118–201CrossRefGoogle Scholar
  5. 5.
    Gupta MA, Gupta AK, Ellis CN, et al. Some psychosomatic aspects of psoriasis. Adv Dermatol 1990; 5: 21–32PubMedGoogle Scholar
  6. 6.
    Roenigk RK, Roenigk HH. Sex differences in the psychological effects of psoriasis. Cutis 1978; 21: 529–33PubMedGoogle Scholar
  7. 7.
    Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236–44PubMedCrossRefGoogle Scholar
  8. 8.
    Yasuda H, Kobayashi H, Ohkawara A. A survey of the social and psychological effects of psoriasis. Jpn J Dermatol 1990; 100: 1167–71Google Scholar
  9. 9.
    Haisma HH, Kaptain AA, Thio B, et al. Social aspects of psoriasis, the Psoriasis Disability Index. Presentation at 6th International Congress on Dermatology and Psychiatry; April 20–22: Amsterdam: 1995Google Scholar
  10. 10.
    Long CC, Funnell CM, Collard R, et al. What do members of the National Eczema Society really want? Clin Exp Dermatol 1993; 18: 516–22PubMedCrossRefGoogle Scholar
  11. 11.
    Lawson V, Lewis-Jones MS, Owens RG, et al. Family impact of childhood atopic eczema. Br J Dermatol 1995; 133Suppl. 45: 19Google Scholar
  12. 12.
    Finlay AY. Measures of the effect of severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol. In pressGoogle Scholar
  13. 13.
    Marks R, Barton SP, Shuttleworth D, et al. Assessment of disease progress in psoriasis. Arch Dermatol 1989; 125: 235–40PubMedCrossRefGoogle Scholar
  14. 14.
    Finlay AY. Measurement of disease activity and outcome in atopic dermatitis. J Dermatol Treat. In pressGoogle Scholar
  15. 15.
    Fredriksson T, Pettersson U. Severe psoriasis — oral therapy with a new retinoid. Dermatologica 1978; 157: 238–44PubMedCrossRefGoogle Scholar
  16. 16.
    Sowden JM, Berth-Jones J, Ross JS, et al. A multicentre, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of cyclosporin in adult patients with severe refractory atopic dermatitis. Lancet 1991; 338: 137–40PubMedCrossRefGoogle Scholar
  17. 17.
    Finlay AY, Kelly SE. Psoriasis — an index of disability. Clin Exp Dermatol 1987; 12: 8–11PubMedCrossRefGoogle Scholar
  18. 18.
    Root S, Kent G, Al-Abadie MSK. The relationship between disease severity, disability and psychological distress in patients undergoing PUVA treatment for psoriasis. Dermatology 1994; 189: 234–7PubMedCrossRefGoogle Scholar
  19. 19.
    Kent G, Al-Absadie M. The Psoriasis Disability Index — further analyses. Clin Exp Dermatol 1987; 12: 8–11CrossRefGoogle Scholar
  20. 20.
    Finlay AY, Khan GK, Luscombe DK, et al. Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol 1990; 123: 751–6PubMedCrossRefGoogle Scholar
  21. 21.
    Salek MS, Finlay AY. Cyclosporin improves quality of life in psoriasis — does this matter? Br J Dermatol 1993; 129Suppl. 42: 32Google Scholar
  22. 22.
    Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–6PubMedCrossRefGoogle Scholar
  23. 23.
    Kurwa HA, Finlay AY. Dermatology inpatient admission greatly improves life quality. Br J Dermatol. In pressGoogle Scholar
  24. 24.
    Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. Br J Dermatol 1993; 129: 422–30PubMedCrossRefGoogle Scholar
  25. 25.
    Salek MS, Luscombe DK, Walker SR, et al. Cardiovascular disease and quality of life. Br J Clin Pharmacol 1988; 26: 628Google Scholar
  26. 26.
    Simpson NB. Social and economic aspects of acne and the cost-effectiveness of isotretinoin. J Dermatol Treat 1993; 4Suppl. 2: S6–9CrossRefGoogle Scholar
  27. 27.
    Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942–9PubMedCrossRefGoogle Scholar
  28. 28.
    Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporin in severe childhood atopic dermatitis: a multicentre study. Br J Dermatol 1994; 131Suppl. 44: 25Google Scholar
  29. 29.
    Mathias CGT. The cost of occupational skin disease. Arch Dermatol 1985; 121:332–4PubMedCrossRefGoogle Scholar
  30. 30.
    Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1995; 20: 425–9CrossRefGoogle Scholar
  31. 31.
    Molin L. Psoriasis. Acta Derm Venereol (Stockh) 1973; 53Suppl. 72: 1–125Google Scholar
  32. 32.
    Larko O, Swanbeck G. Psoriasis treatment and a day-care centre; clinical aspects and an attempt at a cost-benefit analysis. Acta Derm Venereol (Stockh) 1982; 62: 413–8Google Scholar
  33. 33.
    Finlay AY, Bryden JS. Integrated in-patient and out-patient dermatology management. Clin Exp Dermatol 1989; 14: 7–11PubMedCrossRefGoogle Scholar
  34. 34.
    McCarthy M. An evaluation of a day-care service for psoriasis patients. M Soc Sci thesis, University College Dublin, 1987Google Scholar
  35. 35.
    Sander HM, Morris LF, Phillips CM, et al. The annual cost of psoriasis. J Am Acad Dermatol 1993; 28: 422–5PubMedCrossRefGoogle Scholar
  36. 36.
    Krueger GG, Bergstresser PR, Lowe NJ, et al. Psoriasis. J Am Acad Dermatol 1984; 11: 937–47PubMedCrossRefGoogle Scholar
  37. 37.
    Carmichael AJ, Motley RJ, Finlay AY, et al. Methotrexate associated hepatic complications and monitoring protocols in UK dermatology. Br J Dermatol 1992; 127Suppl. 40: 18Google Scholar
  38. 38.
    Cork M. Economic considerations in the treatment of psoriasis. Dermatol Practice 1993; Jan–Feb: 16–20Google Scholar
  39. 39.
    Wattie JM. Eczema and work. Exchange 1994; 72: 10–11Google Scholar
  40. 40.
    Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: Who cares? Who pays? J Am Acad Dermatol 1993; 28: 699–703PubMedCrossRefGoogle Scholar
  41. 41.
    Herd RM, Tidman MJ, Hunter JAA, et al. The economic burden of atopic eczema: a community and hospital based assessment. Br J Dermatol 1994; 131Suppl. 44: 34Google Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • A. Y. Finlay
    • 1
  1. 1.Department of DermatologyUniversity of Wales College of MedicineCardiffUK

Personalised recommendations